For the first time in over half a century, the U.S. federal government is moving to officially recognize a medical role for cannabis. In December 2025, the White House issued an executive order directing that marijuana be reclassified from a Schedule I to a Schedule III controlled substance. This action represents the most significant shift in federal cannabis policy since the Controlled Substances Act of 1970. But what exactly does this “rescheduling” entail, and what might it mean for cannabis research, patients, and businesses going forward?
Under the federal Controlled Substances Act, drugs are sorted into “schedules” based on their accepted medical uses and potential for abuse. For decades, cannabis sat in Schedule I – the strictest category – alongside heroin and LSD, defined as having no accepted medical use and a high abuse risk. Moving marijuana to Schedule III indicates a major change: the government now acknowledges that cannabis has legitimate medical uses and a lower risk profile than Schedule I drugs. (Schedule III substances include common medications like ketamine, anabolic steroids, and certain codeine painkillers.) In short, rescheduling is a formal recognition that cannabis is not on the same level as the most dangerous narcotics, at least in the eyes of federal law.
This policy shift did not happen overnight. It was set in motion by scientific and political developments over the past few years. In 2023, the Department of Health and Human Services (HHS) completed a scientific review and officially recommended that cannabis be moved to Schedule III. HHS based its recommendation on evidence that marijuana can help treat conditions like chronic pain, chemotherapy-related nausea and vomiting, and anorexia due to illness. Following this, the Drug Enforcement Administration (DEA) began a formal rescheduling process in 2024, receiving nearly 43,000 public comments on the proposed change. By late 2025, federal officials – noting the strong medical case and public support – moved to speed things up. A presidential order in December 2025 directed the Justice Department to take all necessary steps to finalize the rescheduling of marijuana as quickly as possible. In effect, the federal government is finally acting on a broad consensus that its cannabis policies must catch up with scientific findings and state-level realities.
The push to reschedule also reflects the glaring disconnect between federal law and everyday practice. Tens of millions of Americans now use cannabis products for health or personal reasons, and forty states plus Washington D.C. have established legal medical marijuana programs. More than 30,000 healthcare practitioners across 43 states have recommended cannabis to over 6 million registered patients for conditions ranging from pain to chemotherapy side effects. Yet until now, federal law insisted that marijuana had no accepted medical use, a stance that severely hindered formal research even as usage became mainstream. Decades of Schedule I status made it extraordinarily difficult for scientists to study cannabis's benefits and risks. By rescheduling, Washington is acknowledging what many patients and doctors have long understood: cannabis can have genuine medical value, and it's time to investigate it seriously.
One of the biggest expected benefits of rescheduling is a dramatic reduction in the barriers to scientific research. Under Schedule I, researchers faced cumbersome approval processes, limited supply options, and strict security requirements – so much so that conducting large, controlled trials on cannabis was nearly impossible. Rescheduling cannabis will make it easier to conduct research into both its potential harms and benefits, explains Mark Ilgen, Ph.D., a University of Michigan addiction researcher. In the Schedule I era, scientists had to rely on lower-quality evidence because regulations made rigorous randomized controlled trials infeasible. The change to Schedule III essentially opens the door to conducting these crucial studies under real-world conditions, which could greatly improve the quality of guidance that healthcare providers can give patients considering cannabis.
Academic institutions and funding agencies may also become more willing to support cannabis studies after rescheduling. In the past, universities and researchers often hesitated to pursue cannabis science, fearing legal complications or risking their federal research funding. Now that the federal government is officially recognizing marijuana's medical potential, experts believe many of those fears will subside. This federal acknowledgment may embolden institutions and leaders who were previously concerned about engaging in cannabis research to start working in this space, says Kevin Boehnke, Ph.D., a pain researcher at the University of Michigan. The hope is that a wave of new studies will rapidly expand our understanding of cannabis – from its effectiveness in treating various conditions to its safety profile and optimal dosing. In time, easier research access should translate into more evidence-based consensus on when and how cannabis can be used therapeutically, replacing guesswork with data.
Rescheduling cannabis could also accelerate the development of cannabis-based medicines. With the plant's medical value now acknowledged, universities and pharmaceutical companies are expected to ramp up research into cannabinoids and their therapeutic applications. Lower regulatory hurdles make it easier to run clinical trials and test cannabis-derived compounds for new treatments. This shift may spur the creation of cannabinoid-based drugs and therapies for pain management, neurological disorders, PTSD, and other conditions that patients have been self-treating with cannabis. In fact, even before rescheduling, the Food and Drug Administration had approved a handful of cannabis-related medications – for example, a purified CBD drug for severe epilepsy and synthetic THC drugs for chemotherapy nausea. However, these remain relatively few. By making formal research and development less onerous, Schedule III status paves the way for more FDA-approved cannabis-derived treatments in the future, potentially expanding beyond the limited uses currently covered. For consumers, this could eventually mean access to cannabis-based medicines that have passed rigorous clinical testing for safety and efficacy, available by prescription just like any other medication.
Federal rescheduling may prove especially significant for military veterans, who as a group suffer high rates of chronic pain, PTSD, and other conditions that cannabis might help. The Department of Veterans Affairs (VA) has historically been constrained by marijuana's Schedule I status, but a Schedule III designation will make it easier for the VA to conduct research on cannabis as a potential treatment for pain management, anxiety, and other veteran health issues. VA researchers already have a number of studies underway, and this policy change promises to expand those efforts. That said, rescheduling does not immediately change VA clinical policy: VA doctors still cannot prescribe or recommend medical marijuana to patients because federal law continues to prohibit it in practice. Any such change would require new legislation. Veterans who live in states with medical cannabis programs can discuss cannabis use with their VA providers – and importantly, VA policy does protect patients from losing their benefits for participating in state-legal marijuana programs. Lawmakers have introduced bills to further ensure that veterans are not penalized for using cannabis as medicine. Major veterans' organizations, including the American Legion, have applauded the rescheduling move, noting that Schedule I status blocked large-scale clinical trials for PTSD, TBI, anxiety, depression, and chronic pain. In short, rescheduling lays the groundwork for more veteran-focused cannabis research that could lead to better evidence-based treatment options.
The rescheduling of marijuana is also poised to bring tangible benefits to the cannabis industry and by extension to consumers. One immediate change is tax relief: once cannabis is Schedule III, state-licensed cannabis businesses will no longer be subject to the punitive IRS rule known as Section 280E, which barred them from deducting normal business expenses. In practical terms, this means dispensaries, growers, and other operators will be able to write off routine costs like rent, payroll, and utilities, just as any other business can. Eliminating the 280E tax penalty could dramatically improve profit margins and cash flow in the legal cannabis sector, potentially enabling lower prices or greater investment in quality and innovation.
Rescheduling may also gradually improve the industry's access to banking and financial services. While it does not force banks to work with cannabis companies, the reduced federal risk profile is expected to encourage more financial institutions to consider servicing state-legal marijuana businesses. Many banks have stayed away under Schedule I, but with cannabis deemed a Schedule III substance, things like loans, credit lines, payment processing, and insurance should become easier to obtain. Industry leaders have described the shift as a transformative policy change that could help the sector reach its full potential by serving patients, creating jobs, unlocking economic growth, and reversing decades of prohibitionist policies. Analysts also predict that major institutional investors who were previously wary may now be more inclined to invest in cannabis enterprises. In summary, Schedule III status signals a new era for the legal cannabis market – one with fairer tax treatment, better access to capital, and a path toward mainstream legitimacy.
It is important to note that federal rescheduling is not the same as legalization, and many legal complexities will persist. Even if marijuana becomes Schedule III, it will remain a controlled substance, and using or selling cannabis outside the bounds of state laws and medical supervision will still violate federal law. People will not suddenly be able to ship cannabis across state lines or buy it at a pharmacy without a prescription. All cannabis products, aside from low-THC hemp, will continue to be subject to the federal Food, Drug, and Cosmetic Act, meaning any product intended for medical use must receive FDA approval before it can be marketed or transported interstate.
Broader reforms will require further action by lawmakers and regulators. Rescheduling alone does not automatically resolve issues like banking restrictions or the ban on interstate commerce of cannabis. Comprehensive federal legislation – such as the SAFE Banking Act or broader descheduling efforts – would be needed to address those gaps. As of early 2026, the DEA must still complete its rulemaking process to formally implement the new schedule, and that process could face legal challenges. Nevertheless, with a presidential mandate and widespread public support, most experts anticipate that the Schedule III change will be realized in the near future. When it does, it will mark a milestone: the federal government aligning its cannabis policy more closely with science and public opinion. Federal rescheduling is a pivotal first step toward a more evidence-driven and accessible future for cannabis, not the end of the journey.
Sources: The White House; Congress.gov; Michigan Medicine; Military Times; MJBizDaily; JD Supra
